Get the Stockscreener App
3.035
1.79%
-0.045
Editas Medicine Inc stock is traded at $3.035, with a volume of 1.72M.
It is down -1.79% in the last 24 hours and down -22.83% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$3.08
Open:
$3.11
24h Volume:
1.72M
Relative Volume:
0.71
Market Cap:
$272.91M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-1.0538
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-6.92%
1M Performance:
-22.83%
6M Performance:
+84.45%
1Y Performance:
+3.95%
1-Day Range:
$2.87
$3.11
1-Week Range:
$2.87
$3.365
52-Week Range:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.035 | 276.95M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.68 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.21 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.25 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.18 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Can Editas Medicine Inc. stock sustain market leadershipJuly 2025 Market Mood & AI Based Buy/Sell Signal Reports - newser.com
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - The Manila Times
Editas Medicine unveils EDIT-401 data at AHA 2025 - Traders Union
Editas Medicine Announces EDIT-401 Poster Presentation at - GlobeNewswire
Will Editas Medicine Inc. stock continue upward momentumWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Should you hold or exit Editas Medicine Inc. nowTreasury Yields & Long-Term Growth Plans - newser.com
Can Editas Medicine Inc. stock weather global recessionMarket Performance Summary & Verified Momentum Stock Alerts - newser.com
Backtesting results for Editas Medicine Inc. trading strategiesJuly 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Should I hold or sell Editas Medicine Inc. stock in 2025Portfolio Return Report & Weekly High Momentum Picks - newser.com
What moving averages say about Editas Medicine Inc.July 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Institutional scanner results for Editas Medicine Inc.Dip Buying & Stepwise Trade Signal Implementation - newser.com
Combining price and volume data for Editas Medicine Inc.Wall Street Watch & Risk Managed Investment Signals - newser.com
How Editas Medicine Inc. (8EM) stock valuation compares with sector2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
Why analysts raise outlook for Editas Medicine Inc. (8EM) stock2025 Dividend Review & Community Consensus Trade Signals - newser.com
Is Editas Medicine Inc. stock a smart buy before Fed meetingJuly 2025 Earnings & Real-Time Volume Analysis - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsGlobal Markets & Daily Price Action Insights - newser.com
Why analysts remain bullish on Editas Medicine Inc. stockJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
Is Editas Medicine Inc. stock attractive after correctionMarket Activity Report & Consistent Profit Trading Strategies - newser.com
How currency fluctuations impact Editas Medicine Inc. stockPortfolio Gains Report & Weekly Market Pulse Alerts - newser.com
Can Editas Medicine Inc. stock sustain institutional interestJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How to build a dashboard for Editas Medicine Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies - TipRanks
Can Editas Medicine Inc. stock withstand economic slowdownOil Prices & High Conviction Buy Zone Alerts - newser.com
How institutional ownership impacts Editas Medicine Inc. stockJuly 2025 Volume & Community Verified Trade Signals - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationJuly 2025 Analyst Calls & Daily Profit Maximizing Trade Tips - newser.com
Full technical analysis of Editas Medicine Inc. stockPortfolio Performance Summary & Capital Protection Trading Alerts - newser.com
Does Editas Medicine Inc. qualify in momentum factor screeningPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will Editas Medicine Inc. stock beat EPS estimates2025 Biggest Moves & Precise Entry and Exit Recommendations - newser.com
Editas Medicine Stock Fell 13% in a Day, What Now? - Trefis
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):